The FDA approved eteplirsen, Sarepta’s treatment for Duchenne muscular dystrophy, Monday after a long and contentious internal debate. After news of the approval, the company’s shares skyrocketed 74 percent to $48.94 Monday. Sarepta stock rose 14 percent more Tuesday when the company received favorable patent decisions resolving a dispute with BioMarin Pharmaceutical. On Wednesday Sarepta’s stock rose 0.9 percent and then another 0.7 percent after hours to $56.59 percent, according to the report.
The company filed a shelf registration in February for the potential sale of its securities, according to the report. Underwriters for the stock include J.P. Morgan, Goldman Sachs and Credit Suisse.
In June, Sarepta held a smaller stock sale of 2.1 million shares for $17.84 each, according to the report.
More articles on supply chain:
Trucking volumes rebound in August
5 reasons insurance claims should include UDIs
Sarepta’s drug approval: The rise of consumer input or the fall of drug standards?
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
